Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Jazz Pharmaceuticals PLC(JAZZ)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for JAZZ
11/03/2026: JAZZ (4-star) is currently NOT-A-BUY. Pass it for now.
Jazz Pharmaceuticals is a biopharmaceutical company specializing in neuroscience and oncology treatments for patients with high unmet medical needs. The company's primary strength lies in its established, high-margin commercial franchises like Xywav and Epidiolex, which anchor its revenue. Its growth story centers on expanding these existing brands into new indications while advancing its clinical pipeline. However, the firm faces significant risks, including pending patent expirations, substantial debt from past acquisitions, and increasing competitive pressure. It may best suit growth-oriented investors comfortable with biotech volatility, while income-seeking investors should note the absence of a dividend. Ongoing monitoring of clinical data and patent litigation remains critical.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Jazz consistently reinvests in high-potential, specialized therapies that offer significant market expansion opportunities. |
| Momentum investor | Mixed fit | Momentum depends on clinical trial data readouts and consistent earnings beats, which are typical for biotech but inherently volatile. |
| Value investor | Strong fit while signal remains positive | The stock often trades at a discount to traditional large-cap pharma due to patent cliffs, potentially offering value if growth continues. |
| Dividend investor | Weak fit | The company does not pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | The inherent risks of clinical development, regulatory approval, and patent challenges create significant volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical news and regulatory decisions. |
| Valuation risk | Medium | Future growth expectations are baked into the price, leaving little room for error on product performance. |
| Competition risk (generic/biosimilar) | High | The primary threat is the loss of patent exclusivity for core revenue drivers like Xyrem. |
| Business quality | Strong | The company has established high-quality, high-margin franchises in niche therapeutic areas. |
| Dividend income | Low / none | Capital is allocated to growth rather than distributions. |
| Execution risk | Medium | Successfully managing a complex global supply chain and regulatory environment is critical to maintaining margins. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 73.73% | Avg. Invested days 70 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/03/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.92B USD | Price to earnings Ratio 63.44 | 1Y Target Price 295.36 |
Price to earnings Ratio 63.44 | 1Y Target Price 295.36 | ||
Volume (30-day avg) 858.4K shares | Beta 0.37 | 52 Weeks Range 128.80 - 266.38 | Updated Date 11/03/2026 |
52 Weeks Range 128.80 - 266.38 | Updated Date 11/03/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.38 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Neuroscience | Includes sales of Xyrem, Xywav, and Sunosi (historically). | This segment is the historical backbone of the company's cash flow. |
| Oncology | Includes sales of Epidiolex, Vyxeos, Rylaze, and Defitelio. | This is the primary growth engine for long-term portfolio diversification. |
| Geography | Sales across North America and International markets. | Most revenue is generated in the US, making the company sensitive to US healthcare pricing policy. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 63.44 | Forward PE 9.78 | Enterprise Value 16.23B | Price to Sales(TTM) 3.03 |
Enterprise Value 16.23B | Price to Sales(TTM) 3.03 | ||
Enterprise Value to Revenue 3.53 | Enterprise Value to EBITDA 10.04 | Shares Outstanding 64.91M | Shares Floating 62.99M |
Shares Outstanding 64.91M | Shares Floating 62.99M | ||
Percent Insiders 2.9 | Percent Institutions 103.88 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.